BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 44.30
+0.35 (0.80%)
Oct 31, 2025, 1:30 PM CST
BioGend Therapeutics Revenue
BioGend Therapeutics had revenue of 52.72M TWD in the quarter ending June 30, 2025, with 41.46% growth. This brings the company's revenue in the last twelve months to 195.02M, up 46.14% year-over-year. In the year 2024, BioGend Therapeutics had annual revenue of 167.65M with 52.53% growth.
Revenue (ttm)
195.02M
Revenue Growth
+46.14%
P/S Ratio
28.23
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.65M | 57.74M | 52.53% |
| Dec 31, 2023 | 109.91M | 78.46M | 249.51% |
| Dec 31, 2022 | 31.45M | 22.18M | 239.26% |
| Dec 31, 2021 | 9.27M | 7.88M | 565.40% |
| Dec 31, 2020 | 1.39M | -68.00K | -4.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| PharmaEssentia | 12.63B |
| Pegavision | 6.90B |
| Center Laboratories | 1.60B |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Caliway Biopharmaceuticals | 44.83M |